Insmed reported $-321686000 in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
DBV Technologies USD -41875000 14.8M Jun/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
Insmed USD -321686000 65.1M Jun/2025
Novartis USD 4.04B 1.22B Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025